How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies

Health Affairs, 04/18/2012

This suggests that current technology assessments, which often determine access to such cancer therapies, may be missing an important source of value to patients and should either incorporate hope into the value of therapies or set a higher threshold for an acceptable cost–effectiveness ratio in the end–of–life context.

Print Article Summary Cat 2 CME Report